reduce basal insulin dose when starting glp-1 receptor agonist Initiation and Titration in Patients With Type 2 Diabetes Beyond Basal Insulin: How Glucagon-Like
Description
Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management
Full dose or microdose
Preclinical studies suggest that GIPR antagonism helps with weight loss and metabolic improvements
Yet, data on their safety and clinical utility during these reproductive windows remain limited
Policy and Global Health Policy advances in 2025 laid critical groundwork for the next phase of obesity care
